Recent studies have highlighted the substantial impact of STK11 mutations in the highly prevalent KRAS-driven NSCLC adenocarcinomas, presenting distinct biological characteristics, therapeutic susceptibilities, and immune profiles (Skoulidis et al, 2018). Here, KRAS is linked to adenocarcinoma.